ARATECAN
LIVE

Serial Number

79448735

Owner

Araris Biotech AG

Filing Date

Dec 15, 2025

Add to watchlist:

No watchlists yet
View on USPTO

ARATECAN Trademark

Serial Number: 79448735

ARATECAN is a trademark filed by Araris Biotech AG on December 15, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Araris Biotech AG (4 trademarks)

Riedhofstrasse 11

Entity Type: 98

Trademark Details

Filing Date

December 15, 2025

Registration Date

Not Registered

Goods & Services

Peptides, peptide derivatives, proteins, glycans, lipids, active principle antibody conjugates, antibody fragments, antibody derivatives, vectors for scientific use; chemical, biological, biotechnological and molecular genetic preparations, namely polypeptides and proteins for reagent development or production for industrial and scientific applications; biological preparations, namely, polypeptides, peptide derivatives for laboratories and analysis for industrial and scientific applications; chemical and biochemical substances for manufacturing pharmaceutical products.

Provision of information with respect to business contacts for research projects.

Scientific, medical, biological, molecular genetic, chemical, pharmaceutical and technological research, in the field of biochemistry or pharmacy; biochemical or pharmaceutical laboratory services; industrial analysis and research services; development and experimentation of medicines; conducting preclinical and clinical trials; laboratory services for the benefit of third parties; scientific advisory services in the biochemical, biological and molecular genetic fields; scientific advice for the pharmaceutical industry sector; analysis services for medical and pharmaceutical research services in connection with the treatment of individuals, included in class 42; provision of scientific research information and results.

Pharmaceutical products and medical preparations in the field of cancer therapy; biopharmaceuticals and medical preparations in the field of active antibody conjugates; chemical, biological, molecular and biochemical genetic and biopharmaceutical products for medical and pharmaceutical use, namely peptides, peptide derivatives, active principle antibody conjugates, antibody fragments, antibody derivatives, vectors; pharmaceutical products and substances for disease treatment and preparations for medical treatments.

Filing History

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 12, 2026 RFCR
NON-FINAL ACTION WRITTEN
May 11, 2026 CNRT
ASSIGNED TO EXAMINER
Apr 25, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 24, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 24, 2026 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 23, 2026 REPR